World's Best Scientists 2026 revealed!
Christophe Hézode

Christophe Hézode

D-Index & Metrics

Medicine

D-Index
81
Citations
25442
World Ranking
16579
National Ranking
542

Christophe Hézode publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christophe Hézode sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 360 publications — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christophe Hézode D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christophe Hézode sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 81 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Christophe Hézode is affiliated with Université Paris Cité in France. Their research primarily spans the field of Medicine, with a focus on epidemiology, hepatology, and infectious diseases. This work encompasses studies related to liver diseases, viral infections, and treatments.

The scientist's recent publications highlight a strong interest in liver disease diagnosis and treatment as well as viral hepatitis. Notable papers include:

  • Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials (2020, Journal of Hepatology)
  • Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta (2020, Journal of Hepatology)
  • Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs (2020, Open Forum Infectious Diseases)
  • Evaluation of the Xpert HBV Viral Load for hepatitis B virus molecular testing (2020, Journal of Clinical Virology)
  • Performance of rapid diagnostic tests for hepatitis B surface antigen detection in serum or plasma (2021, Diagnostic Microbiology and Infectious Disease)

Frequent co-authors who have collaborated with Hézode include:

  • Stéphane Chevaliez
  • Jean-Michel Pawlotsky
  • Françoise Roudot-Thoraval
  • Isabelle Rosa
  • V. Loustaud-Ratti

Hézode's research has been published predominantly in medical journals specializing in liver and viral diseases. The main publication venues include:

  • Journal of Hepatology
  • Journal of Clinical Virology
  • Open Forum Infectious Diseases
  • Viruses
  • Diagnostic Microbiology and Infectious Disease

Their main areas of study reflect a focus on:

  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Hepatitis B Virus Studies
  • Liver Disease and Transplantation
  • HIV/AIDS drug development and treatment
  • Hepatitis Viruses Studies and Epidemiology
  • Viral Infections and Outbreaks Research

This profile indicates a dedicated involvement in hepatology and viral infectious disease research, reflected through contributions to understanding hepatitis viruses and improving screening and diagnostic methods. The collaboration network includes several frequent co-authors contributing to this scientific domain alongside Hézode.

Best Publications

  • Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

    Devin Razavi-Shearer;Ivane Gamkrelidze;Mindie H Nguyen;Ding-Shinn Chen

  • Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

    Christophe Hézode;Nicole Forestier;Geoffrey Dusheiko;Peter Ferenci

  • Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

    Jordan J. Feld;Ira M. Jacobson;Christophe Hézode;Tarik Asselah

  • ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

    Fred Poordad;Christophe Hezode;Roger Trinh;Kris V. Kowdley

  • Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

    Stefan Zeuzem;Geoffrey M. Dusheiko;Riina Salupere;Alessandra Mangia

  • Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

    Fabrice Carrat;Hélène Fontaine;Céline Dorival;Mélanie Simony

  • Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890

    Christophe Hézode;Hélène Fontaine;Céline Dorival;Dominique Larrey

  • Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.

    Christophe Duvoux;David Zanditenas;Christophe Hézode;Anthony Chauvat

  • Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients

    Keyur Patel;Stuart C. Gordon;Ira Jacobson;Christophe Hézode

  • Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

    Christophe Hézode;Christophe Hézode;Françoise Roudot-Thoraval;Françoise Roudot-Thoraval;Son Nguyen;Pascale Grenard

  • Historical epidemiology of hepatitis C virus (HCV) in selected countries

    P. Bruggmann;T. Berg;A. L. H. Øvrehus;C. Moreno

  • Antiviral strategies in hepatitis C virus infection.

    Christoph Sarrazin;Christophe Hézode;Christophe Hézode;Stefan Zeuzem;Jean-Michel Pawlotsky;Jean-Michel Pawlotsky

  • Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

    Mark Sulkowski;Christophe Hezode;Jan Gerstoft;John M Vierling

  • Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies

    Castéra L;Hézode C;Roudot-Thoraval F;Bastie A

  • Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

    Marc Bourlière;Jean Pierre Bronowicki;Victor de Ledinghen;Christophe Hézode

  • Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

    Christophe Hézode;Tarik Asselah;K Rajender Reddy;Tarek Hassanein

  • Antiviral action of ribavirin in chronic hepatitis C.

    Jean Michel Pawlotsky;Harel Dahari;Avidan U. Neumann;Christophe Hezode

  • Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis

    Christophe Hézode;Helene Fontaine;Celine Dorival;Fabien Zoulim

  • Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)

    Vincent Leroy;Peter W Angus;Jean-Pierre Bronowicki;Gregory J Dore

  • Strategies to manage hepatitis C virus (HCV) disease burden

    H Wedemeyer;A S Duberg;M Buti;W M Rosenberg

Frequent Co-Authors

Stanislas Pol
Stanislas Pol Université Paris Cité
Françoise Roudot-Thoraval
Françoise Roudot-Thoraval Assistance Publique – Hôpitaux de Paris
Dominique Larrey
Dominique Larrey University of Montpellier
Jean-Pierre Bronowicki
Jean-Pierre Bronowicki University Hospital of Nancy
Marc Bourlière
Marc Bourlière Hôpital Saint Joseph
Daniel Dhumeaux
Daniel Dhumeaux Grenoble Alpes University
Laurent Alric
Laurent Alric Federal University of Toulouse Midi-Pyrénées
Albert Tran
Albert Tran Inserm : Institut national de la santé et de la recherche médicale

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in flexible routes to a career in healthcare, online medical and nursing programs offer a range of accelerated and convenient pathways. Many choose accelerated dnp programs to earn their Doctor of Nursing Practice degree more efficiently, paving the way for leadership roles in clinical settings.

If you’re seeking a less intensive route, there are also easiest dnp programs that focus on balancing rigorous training with manageable course structures, appealing to working professionals.

Aspiring nurses looking for a quick start may consider fast track lpn programs online, which allow students to qualify as Licensed Practical Nurses in less time than traditional programs.

For those interested in mental health care, accelerated msn psychiatric np programs provide a fast pathway to becoming a Psychiatric Mental Health Nurse Practitioner—a role in growing demand across the country.

These options allow students to advance their medical careers with flexibility, making healthcare education more accessible than ever.

Best Scientists Citing Christophe Hézode

Trending Scientists

Recently Published Articles